Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
With a market cap of 327.26B, Merck(MRK) trades at $132.51. The stock has a price-to-earnings ratio of 140.71 and currently yields dividends of 2.47%.
As of 2026-11-20, Merck(MRK) stock has fluctuated between $131.36 and $139.17. The current price stands at $132.51, placing the stock +0.9% above today's low and -4.8% off the high.
The Merck(MRK)'s current trading volume is 13.6M, compared to an average daily volume of 7.9M.
During the past year, Merck(MRK) stock moved between $93.90 at its lowest and $156.92 at its peak.
During the past year, Merck(MRK) stock moved between $93.90 at its lowest and $156.92 at its peak.
MRK News
Merck (NYSE:MRK) announced a new AI-focused drug discovery collaboration with Alphabet unit Isomorphic Labs centered on oncology research. The company said it...
Halozyme (HALO) provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck (MRK) to re...
Merck (MRK) is joining hands with AI-driven drug discovery firm Isomorphic Labs to discover drug candidates against cancer, the companies announced on Thursday....
Analyst ratings
65%
of 31 ratingsMore MRK News
Merck (MRK) and Isomorphic Labs, an AI-first drug design and development company, announced a research collaboration that brings together Isomorphic Labs’ AI ap...
Merck & Company ( (MRK) ) has provided an announcement. On Nov. 16, 2026, Thomas H. Glocer notified Merck of his intention to retire from its board at the May...
Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational,...
Merck (MRK Quick QuoteMRK - Free Report) has made considerable progress in advancing the pipeline, particularly in areas like oncology, vaccines and infec...
Merck (MRK) announced that Thomas Glocer intends to retire from the Merck Board of Directors at the company’s Annual Meeting of Shareholders in May 2027. The in...
Merck ends development of BTK inhibitor nemtabrutinib Nov 17, 2026, 5:05 PM ET Merck & Co., Inc. (MRK) Stock By : Jonathan Block, SA News Editor Merck ( MRK non...
Merck (MRK) announced the discontinuation of the clinical development program evaluating nemtabrutinib, an investigational, oral, non-covalent Bruton’s tyrosine...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.